Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?
You may also be interested in...
Outgoing Pharmaceutical Care Management Association chief discusses fight over rebates, future of pharmacy benefit management, opportunities and challenges facing his successor.
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.